Early intervention with daratumumab for smoldering myeloma may delay disease progression
Researchers observed delayed progression to multiple myeloma (MM) in patients with smoldering MM (SMM) who were treated with single-agent daratumumab.
Multiple Myeloma
News
Lymphoma
EMA approves OT-C001 trial in DLBCL
The European Medicines Agency (EMA) has approved an Investigational Medicinal Product Dossier (IMPD) for OT-C001.
Leukemia
Acute Myeloid Leukemia
News
Triplet ‘effective’ in relapsed or refractory AML
A phase 2 study found that cladribine, idarubicin, and cytarabine (CLIA) was “effective” in treating relapsed or refractory acute myeloid leukemia (AML).
Multiple Myeloma
News
Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma
A real-world, multicenter study supported findings from the pivotal ICARIA-MM clinical trial, showing that isatuximab, pomalidomide, and dexamethasone (IsaPd) was an efficacious and tolerable
Society Updates
Registration open for 13th Annual Meeting of the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) has opened registration for its annual meeting; register before June 8, 2025, for early-bird rates. Event dates: September
Lymphoma
News
Early-phase trial shows promise for refractory CD30-positive lymphoma
A CD30/CD16A bispecific antibody, AFM13, “showed encouraging preliminary safety and efficacy
Lymphoma
Aggressive B-Cell Lymphomas
ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL
Odronextamab monotherapy resulted in a 48.3% overall response rate in patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after chimeric antigen
News
Video Interviews
Dr. Kidson-Gerber discusses guidelines for pregnant patients with blood cancers
Giselle Kidson-Gerber, FRACP, FRCPA, a hematologist and clinical researcher at Prince of Wales Hospital and the Royal Hospital for Women, Sydney, discusses the
Cellular Therapy
Early-phase study shows promise of novel CAR-T talicabtagene autoleucel for B-cell malignancies
The novel chimeric antigen receptor (CAR) T-cell therapy talicabtagene autoleucel induced durable responses in an Indian population with relapsed or refractory B-cell malignancies,
News
Phase 3 trial recruiting for quizartinib plus chemotherapy in FLT3-ITD-negative AML
The phase 2 PETHEMA-QUIWI study of quizartinib plus chemotherapy showed significantly improved overall survival (OS) and served as the backbone for this new